The tweet was deleted by the author.
But we saved everything 🙂.
Stereotaxis has treated 70 patients with arrhythmia since the program launch in July, reaching individuals across the full spectrum of arrhythmias, including those with histories of multiple failed procedures.
The company noted strong early demand and patient impact after a short period of service. Stereotaxis' technological innovations continue to expand access to advanced cardiac treatments.
View post on X Loading...
Stereotaxis recently broadened its technology portfolio with the launch of the MAGiC ablation tip, designed for efficient energy delivery. The company has also experienced rising activity in robotic electrophysiology, as detailed in a previous update on sector momentum and expected growth. These developments align with ongoing efforts to improve treatment options for cardiac arrhythmia patients.